Ameriprise
MIRM icon

Ameriprise’s Mirum Pharmaceuticals MIRM Stock Holding History

Ameriprise’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3M Sell
219,255
-52,225
-19% -$4.91M ﹤0.01% 1400
2025
Q4 		$21.4M Buy
271,480
+68,412
+34% +$4.91M ﹤0.01% 1365
2025
Q3 		$14.9M Sell
203,068
-39,692
-16% -$2.52M ﹤0.01% 1612
2025
Q2 		$12.4M Buy
242,760
+46,877
+24% +$2.09M ﹤0.01% 1662
2025
Q1 		$8.82M Buy
195,883
+1,807
+0.9% +$85.2K ﹤0.01% 1853
2024
Q4 		$8.02M Buy
194,076
+10,732
+6% +$447K ﹤0.01% 1981
2024
Q3 		$7.15M Buy
183,344
+168,037
+1,098% +$6.7M ﹤0.01% 2107
2024
Q2 		$523K Sell
15,307
-3,720
-20% -$97.5K ﹤0.01% 3401
2024
Q1 		$478K Sell
19,027
-11,550
-38% -$318K ﹤0.01% 3434
2023
Q4 		$903K Buy
30,577
+180
+0.6% +$5.45K ﹤0.01% 3225
2023
Q3 		$961K Buy
30,397
+13,314
+78% +$365K ﹤0.01% 3159
2023
Q2 		$442K Sell
17,083
-1,882
-10% -$50.1K ﹤0.01% 3487
2023
Q1 		$456K Buy
+18,965
New +$432K ﹤0.01% 3466

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ameriprise's MIRM Position: Q1 2026 in Review

Ameriprise reduced its Mirum Pharmaceuticals (MIRM) stake by 19% in Q1 2026, selling an estimated $4.91M and leaving 219,255 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1400.

Ameriprise first reported a position in MIRM in Q1 2023 and has held it in 13 quarters since. The position peaked at $21.4M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Ameriprise held 219,255 shares of Mirum Pharmaceuticals worth $20.3M as of Q1 2026.
  • Ameriprise sold 52,225 Mirum Pharmaceuticals shares in Q1 2026, an estimated $4.91M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1400 holding.
  • Ameriprise first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Ameriprise's Mirum Pharmaceuticals position peaked at $21.4M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.